Non|Metastatic Castration| Resistant Prostate Cancer

Non-Metastatic Castration- Resistant Prostate Cancer

Prostate cancer happens when abnormal cells form and grow in the prostate gland. Unlike benign (or non-cancerous) growths, these growths are cancerous ( ...

Treatments for castration-resistant prostate cancer

It can also be called hormone-refractory or hormone-resistant prostate cancer. Non-metastatic castration-resistant prostate cancer has not spread to other parts ...

Nonmetastatic Castration-Resistant Prostate Cancer - PubMed Central

The majority of the patients with nonmetastatic castration-resistant prostate cancer will eventually develop metastatic lesions, associated with ...

Treatment of nonmetastatic castration-resistant prostate cancer

Nonmetastatic castration-resistant prostate cancer (nmCRPC) is defined as a rising prostate-specific antigen concentration, despite castrate ...

Castration-Resistant Prostate Cancer: What to Know - WebMD

Metastatic CRPC. This is when the prostate cancer has spread, or metastasized, to other parts of the body, such as the bones and lymph nodes.

Nonmetastatic castration-resistant prostate cancer: Novel agents to ...

Nonmetastatic castration-resistant prostate cancer (nmCRPC) - defined as prostate-specific antigen (PSA) > 2 ng/mL, testosterone castration levels < 1.7 ...

The past, present, and future of non-metastatic castration-resistant ...

Background and Objective: Non-metastatic castration-resistant prostate cancer (nmCRPC) is a diverse disease state defined as the absence of radiographic ...

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival ...

Patients with nonmetastatic, castration-resistant prostate cancer are at risk for progression to metastatic disease, which is often accompanied ...

The treatment landscape of nonmetastatic castrate resistant prostate ...

The median duration (months) from diagnosis of metastatic prostate cancer to onset of mCRPC was 11 (IQR 9–23) with a median serum PSA (ng/ml) of 8.6 (IQR 4.0– ...

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostate cancer develops when abnormal cells form and grow in the prostate gland. Unlike benign (or non-cancerous) growths, these are cancerous (malignant).

“Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic ...

Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil

New and Emerging Therapeutics for Non-metastatic Castrate ...

Non-metastatic castrate-resistant prostate cancer (nmCRPC) is an intermediate disease state characterized as prostate cancer that, ...

Overview of the treatment of castration-resistant prostate cancer ...

Outline · Abiraterone · Enzalutamide, apalutamide, and darolutamide · - Metastatic CRPC · - Nonmetastatic CRPC.

Definition of castrate-resistant prostate cancer - NCI Dictionary of ...

Prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels. Many early-stage prostate cancers need ...

Managing Nonmetastatic Castration-resistant Prostate Cancer

(C) PET/CT fusion images, with the arrow pointing at the metastatic deposit. CT=computed tomography; PET=positron emission tomography; PSA= ...

Diagnosed With Metastatic Castration-Resistant Prostate Cancer

With metastatic castration-resistant prostate cancer (mCRPC), or hormone-refractory prostate cancer, your current therapy is no longer ...

Management of Patients with Nonmetastatic Castration‐Resistant ...

Most prostate cancer patients who undergo androgen-deprivation therapy or orchiectomy will eventually develop castration-resistant prostate ...

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant ...

Because metastatic, castration-resistant prostate cancer is associated with decreased overall survival, worsening quality of life, and increased ...

Castration Resistant Prostate Cancer - ScienceDirect.com

Metastatic castration-resistant prostate cancer (mCRPC) is clinically defined as a state where castrate serum testosterone is lower than 50 ng/dL coupled ...

Treatment and trials in non-metastatic castration-resistant prostate ...

Standard treatment for non-metastatic prostate cancer, to prevent metastatic progression, is androgen deprivation therapy (ADT); however, many ...